IAPs and RIPK1 mediate LPS-induced cytokine production in healthy subjects and Crohn’s disease
Jakob Benedict Seidelin(University of Copenhagen), Ole Haagen Nielsen(University of Copenhagen)
Cited by 3
Related Papers
A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn’s Disease
|PLoS ONE|2013|134
Circulating tumour DNA and risk of recurrence in patients with asymptomatic versus symptomatic colorectal cancer
|British Journal of Cancer|2024|10